Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with advanced pulmonary arterial hypertension (PAH), according to the results of a recent study published in Journal of Infectious Diseases. Researchers retrospectively reviewed outcomes of patients with PAH undergoing a surgical procedure...
Latest News
St. Jude Children’s Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Then researchers identified safety concerns with the experimental drug that have implications for current clinical trials in adults. The study appears today in Nature Communications. CX-5461 is...
CAMBRIDGE, Mass.– Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington’s disease (HD). SAGE-718 is in development as a...
SHANGHAI, China — Gannex Pharma Company Ltd, a wholly-owned company of Ascletis Pharma Inc., announced that its strategic partner, Sagimet Biosciences Inc., today reported positive topline results from Sagimet’s FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients with stage 2 or stage 3...
SOMERVILLE, Mass. — Sail Biomedicines, Inc., a Flagship Pioneering company and leader in RNA-based programmable medicines, today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of...
LEXINGTON, Mass. — SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on its novel Gene Coding™ technology, today announced the nomination of a development candidate, SGT-1001, for the treatment of Stargardt disease, a rare and progressive inherited retinal disease. SGT-1001 is being developed as a one-time, non-viral therapy to...
Jurassic Park actor Sam Neill was recently interviewed by The Guardianopens in advance of the release of his memoir, Did I Ever Tell You? Originally planned as a glimpse into his career, his life as a celebrity, and his farm in New Zealand, the book takes a dark turn in...
Basel, Switzerland – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko (natalizumab) in Germany from February 1. Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat RRMS. Tyruko is indicated as a single disease-modifying therapy (DMT) in adults with...
PENNSVILLE TWP. — Sandy McWilliams, a former Pennsville resident, will walk 700 miles this summer from her home in Kentucky to her mother’s house in Pennsville to raise awareness on progressive supranuclear palsy, a rare disease that her mother is fighting. PSP is a rare, fatal brain disease that McWilliams’...
BRISBANE, Calif. – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle...